1.1K(top 0.1%)
papers
26.0K(top 1%)
citations
74(top 1%)
h-index
133(top 1%)
g-index
1.2K
all documents
28.6K
doc citations
2.7K
citing journals
1.1K
times ranked

Top Articles

#TitleJournalYearCitations
1Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology20181,659
2B cells and tertiary lymphoid structures promote immunotherapy responseNature20201,421
3Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor ProgressionPLoS ONE2009686
4An inhibitor of oxidative phosphorylation exploits cancer vulnerabilityNature Medicine2018622
5Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activityLeukemia2018525
6Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaMolecular Therapy2017498
7A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCRBlood2012437
8International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trialsCytotherapy2016400
9Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow TransplantationBiology of Blood and Marrow Transplantation2015342
10Engineering Natural Killer Cells for Cancer ImmunotherapyMolecular Therapy2017337
11Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor ActivityCancer Research2015327
12Double hit lymphoma: the MD Anderson Cancer Center clinical experienceBritish Journal of Haematology2014310
13Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialLancet Oncology, The2012274
14The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancyBlood2016245
15Toward eliminating HLA class I expression to generate universal cells from allogeneic donorsBlood2013243
16Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working groupLeukemia2015242
17Natural killer cells in antitumour adoptive cell immunotherapyNature Reviews Cancer2022208
18Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen–Matched Unrelated and Related DonorsBiology of Blood and Marrow Transplantation2014207
19Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trialLeukemia2013197
20Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapyBlood2013190
21Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trialLancet Oncology, The2016189
22Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapyNature Reviews Clinical Oncology2019178
23Mechanisms of nuclear content loading to exosomesScience Advances2019176
24Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell TransplantationBiology of Blood and Marrow Transplantation2015161
25Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDSBiology of Blood and Marrow Transplantation2008159
26The Warburg Effect in Leukemia-Stroma Cocultures Is Mediated by Mitochondrial Uncoupling Associated with Uncoupling Protein 2 ActivationCancer Research2008153
27Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer VaccinationCancer Research2017152
28Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting CellsPLoS ONE2013143
29US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALLBlood Advances2016142
30Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular TherapyBiology of Blood and Marrow Transplantation2020139
31Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsBiology of Blood and Marrow Transplantation2020138
32Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines CommitteeBiology of Blood and Marrow Transplantation2016130
33PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationBlood2019129
34Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against CancerCancer Discovery2021128
35Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsBiology of Blood and Marrow Transplantation2016127
36Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infectionsJournal of Antimicrobial Chemotherapy2013125
37A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsBlood Advances2020122
38A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19Immunological Reviews2014121
39Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual diseaseLeukemia2014121
40The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemiaCancer2016121
41Advances in understanding the leukaemia microenvironmentBritish Journal of Haematology2014120
42Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicityNature Communications2019120
43Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironmentCancer Biology and Therapy2012119
44Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignanciesBone Marrow Transplantation2007117
45Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cellsJournal of Clinical Investigation2021117
46Batf is important for IL-4 expression in T follicular helper cellsNature Communications2015114
47ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple MyelomaCancer Cell2017114
48Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'Nature Reviews Clinical Oncology2018114
49Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I TrialBiology of Blood and Marrow Transplantation2016113
50Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin LymphomaInternational Journal of Radiation Oncology Biology Physics2015110